Currently, the risk associated with a man’s prostate cancer is classified as low-, intermediate- or high-risk. A new stratification tool (the Cambridge Prognostic Grouping, CPG) classifies men into five categories based on more detailed information about the clinical features of their disease.
In this short report, we examine the impact of using the new way of stratifying the risk of prostate cancer on the way that potential ‘over-treatment’ is measured in the NPCA.
Last updated: 7 September 2022, 3:02pm